Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Bionano Genomics, Inc.

Indicator	TTM Median
P/E	0.00 23.75
Price/Sales	0.31 3.01
P/B	0.23 2.20
P/FCF	0.00 18.30

Indicator	TTM Median
Net Worth	0.02 0.20
Quick Ratio	1.11 1.71
Current Ratio	1.63 2.83

Indicator	TTM Median
Net Profit Margin	-551.35 10.25
Operating Margin	-502.70 14.24
Gross Margin	29.73 68.57

Indicator	TTM Median
EPS	0.32 0.37
EPS Forecast	0.09 0.37
Revenue	8.00M 16.00M
Gross Profit	3.00M —
EBITDA	-15.00M —

Bionano Genomics, Inc.

Indicators BNGO

Valuation

Debts

Efficiency

Other ratios

Revenue